Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DK6P5A
|
|||
| Drug Name |
VDA-1102
|
|||
| Synonyms |
SB18685; 941277-00-5
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Actinic keratosis [ICD-11: EK90.0; ICD-10: L57.0; ICD-9: 702] | Phase 2 | [1] | |
| Company |
Vidac Pharma
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H23NO3
|
|||
| Canonical SMILES |
CCC=CCC1C(CCC1=O)CC(=O)OC2=CC=CC3=C2N=CC=C3
|
|||
| InChI |
1S/C21H23NO3/c1-2-3-4-9-17-16(11-12-18(17)23)14-20(24)25-19-10-5-7-15-8-6-13-22-21(15)19/h3-8,10,13,16-17H,2,9,11-12,14H2,1H3/b4-3+
|
|||
| InChIKey |
AFOGJOMDCIQZNM-ONEGZZNKSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Tissue kallikrein (KLK2) | Target Info | Modulator | [2] |
| Voltage-dependent anion channel (VDAC) | Target Info | Modulator | [2] | |
| KEGG Pathway | Endocrine and other factor-regulated calcium reabsorption | |||
| NetPath Pathway | IL2 Signaling Pathway | |||
| Pathway Interaction Database | Coregulation of Androgen receptor activity | |||
| Regulation of Androgen receptor activity | ||||
| Reactome | Activation of Matrix Metalloproteinases | |||
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | ||||
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | ||||
| WikiPathways | Prostate Cancer | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03538951) Study to Evaluate the Efficacy, Safety, and Tolerability of Topical VDA-1102 Ointment in Subjects With Actinic Keratosis (Phase2b). U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Vidac Pharma. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.